IPO观察丨迈百瑞撤单:财务数据曾存在3.86亿元差错,业务独立性遭质疑

红星新闻
Feb 19, 2025

红星资本局2月19日消息,近日,因烟台迈百瑞国际生物医药股份有限公司(以下简称迈百瑞)撤回发行上市申请,深交所决定终止其发行上市审核。此前,迈百瑞的IPO申请于2022年9月28日获受理,并在2023年6月16日过会,但因未能在规定时间内提交注册材料,公司最终选择撤回申请。红星资本局注意到,迈百瑞在首轮审核问询中即被发现申报材料存在重大错误,扣非净利润前后差异金额达3.86亿元,而迈百瑞的财务部门...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10